Skip to main content
OpenTrials
Completed

NCT Number: NCT06195813

Asparagus Capsule Consumption and Blood Sugar and Lipids and Oxidative Stress

Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–59 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Faculty of Allied Health Sciences, Burapha University

Mueang, Changwat Chon Buri, 20131, Thailand

About this study

The study design was cross-sectional. Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels. Analysis of covariance was used to analyze parameters between groups and paired t-test was used to analyze parameters intra-group.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Man or woman, aged between 18 to 59 years
  • Body mass index more than 23 (Asian criteria)
  • No history of hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer
  • No regular intake of dietary supplements, i.e., vitamins, antioxidants
  • No regular smokers or alcohol drinkers (>2 times per week)
  • Not sportman or regular exerciser (>2 times per week or >150 min per week)
  • No food allergy, especially shoot

Exclusion criteria

  • Current signs or symptoms of infection, i.e., fever, hyperpnea, dyspnea, and palpitations.

Treatment and study plan

Asparagus capsule

Dietary Supplement

Asparagus capsule is categorized as dietary supplement.

Placebo capsule

Other

Placebo capsule is categorized as other.

Primary outcomes

  1. Level of body fat

    Time frame: Day 0 and end of 12 weeks

    Level of body fat was measured in percentage unit

  2. Level of fat mass

    Time frame: Day 0 and end of 12 weeks

    Level of fat mass was measured in kilogram unit

  3. Level of fat distribution

    Time frame: Day 0 and end of 12 weeks

    Level of fat distribution was measured by ratio of waist (centimeter) to hip (centimeter)

  4. Concentration of blood glucose

    Time frame: Day 0 and end of 12 weeks

    Concentration of blood glucose was measured in serum in mmol/L unit

  5. Concentration of blood insulin

    Time frame: Day 0 and end of 12 weeks

    Concentration of blood insulin was measured in serum in uU/mL (microunit/milliliter) unit

  6. Concentrations of blood lipids

    Time frame: Day 0 and end of 12 weeks

    Concentrations of total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured in serum in mg/dL unit

  7. Concentration of blood malondialdehyde

    Time frame: Day 0 and end of 12 weeks

    Concentration of blood malondialdehyde was measured in plasma in uM (micromolar) unit

  8. Concentration of blood protein carbonyl

    Time frame: Day 0 and end of 12 weeks

    Concentration of blood protein carbonyl was measured in plasma in nmol/mg protein unit

Secondary outcomes

  1. Concentrations of blood glucose from oral glucose tolerance test

    Time frame: At 0 minute before glucose consumption and at 30, 60, 90, 120 minutes after glucose consumption

    Concentrations of blood glucose were measured before and after glucose consumption at 75 g/100 ml in mg/dL unit

Sponsors and collaborators

Lead sponsor

Burapha University

Other

Registry information

Official study title

Effects of Asparagus Capsule Consumption on Blood Sugar and Lipids and Oxidative Stress in Overweight and Obese Participants

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jan 8, 2024
Registry last updated
Jan 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.